NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

市场调查报告书

肢端肥大症 - 市场洞察,流行病学,市场预测 ~2027年

Acromegaly and Gigantism Therapeutics - Market Insight, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品编码 602022
出版日期 按订单生产 内容资讯 英文 100 Pages
商品交期: 10个工作天内
价格
肢端肥大症 - 市场洞察,流行病学,市场预测 ~2027年 Acromegaly and Gigantism Therapeutics - Market Insight, Epidemiology and Market Forecast - 2028
出版日期: 按订单生产内容资讯: 英文 100 Pages
简介

主要7个国家(美国、英国、德国、法国、义大利、西班牙、日本)的肢端肥大症的总患病数2016年估计为6万610人。

本报告提供肢端肥大症的相关调查,疾病概要,患者背景,主要7个国家肢端肥大症的患病数、诊断数的预测(今后10年份),已上市药及新药概要,市场成长要素、阻碍因素,市场机会,竞争情形等资讯。

目录

第1章 重要的洞察

第2章 尖端巨大市场概要

  • 市场占有率(最新值)肢端肥大症的分布
  • 市场占有率(预测值)肢端肥大症的分布

第3章 疾病概要:肢端肥大症(ACM)

  • 简介
  • 征兆与症状
  • 下垂体腺瘤的分类
  • 肢端肥大症临床症状
  • 病因
  • 病理生理学
  • 肢端肥大症的遗传性根据
  • 病因
  • 诊断
    • 诊断指南
    • 内分泌学会诊疗指南作成委员(英国)
    • 美国临床内分泌学会(美国)

第4章 流行病学和患者人口

第5章 主要觀察

第6章 主要7个国家的流行病学

  • 肢端肥大症的总患病数

第7章 美国的流行病学

  • 肢端肥大症的总患病数
  • 肢端肥大症的患病数:各原因
  • 肢端肥大症的诊断数
  • 肢端肥大症的诊断数:各腺瘤
  • 肢端肥大症的治疗可能的病例数

第8章 欧盟5国的流行病学

  • 英国
    • 肢端肥大症的总患病数
    • 肢端肥大症的患病数:各原因
    • 肢端肥大症的诊断数
    • 肢端肥大症的诊断数:各腺瘤
    • 肢端肥大症的治疗可能的病例数
  • 德国
    • 肢端肥大症的总患病数
    • 肢端肥大症的患病数:各原因
    • 肢端肥大症的诊断数
    • 肢端肥大症的诊断数:各腺瘤
    • 肢端肥大症的治疗可能的病例数
  • 法国
    • 肢端肥大症的总患病数
    • 肢端肥大症的患病数:各原因
    • 肢端肥大症的诊断数
    • 肢端肥大症的诊断数:各腺瘤
    • 肢端肥大症的治疗可能的病例数
  • 义大利
    • 肢端肥大症的总患病数
    • 肢端肥大症的患病数:各原因
    • 肢端肥大症的诊断数
    • 肢端肥大症的诊断数:各腺瘤
    • 肢端肥大症的治疗可能的病例数
  • 西班牙
    • 肢端肥大症的总患病数
    • 肢端肥大症的患病数:各原因
    • 肢端肥大症的诊断数
    • 肢端肥大症的诊断数:各腺瘤
    • 肢端肥大症的治疗可能的病例数

第9章 日本的流行病学

  • 肢端肥大症的总患病数
  • 肢端肥大症的患病数:各原因
  • 肢端肥大症的诊断数
  • 肢端肥大症的诊断数:各腺瘤
  • 肢端肥大症的治疗可能的病例数

第10章 治疗

  • 肢端肥大症的生物标记
  • 治疗指南
    • 美国临床内分泌学会(美国)
    • 内分泌学会诊疗指南作成委员(英国)

第11章 未满足需求

第12章 上市药

  • Somatuline Depot(醋酸兰瑞肽):Ipsen Biopharmaceuticals
    • 医药品概要
    • 法规的里程碑
    • 优点与缺点
    • 安全性和有效性
    • 产品的简介
  • Somavert (pegvisomant): Pharmacia & Upjohn
  • Sandostatin LAR Depot: Novartis Pharmaceuticals
  • Signifor LAR (pasireotide): Novartis Pharmaceuticals

第13章 竞争情形

第14章 新药

  • IONIS-GHR-LRx:Ionis Pharmaceuticals
    • 产品说明
    • 其他开发活动
    • 临床开发
    • 临床试验资讯
    • 安全性和有效性
    • 产品的简介
  • Octreotide capsules: Chiasma Pharma
  • ATL1103: Antisense Therapeutics
  • CAM2029: Novartis
  • GT-02037: Pharmaspur
  • Veldoreotide: Evotec/ Aspireo Pharmaceuticals

第15章 分析肢端肥大症:主要7个国家

  • 主要的觀察
  • 主要7个国家的肢端肥大症的市场规模

第16章 美国市场预测

  • 市场规模
  • 整体市场规模
  • 市场规模:各治疗药物

第17章 欧盟5国的市场展望

  • 英国的市场规模
    • 市场规模
    • 整体市场规模
    • 市场规模:各治疗药物
  • 德国的市场规模
    • 市场规模
    • 整体市场规模
    • 市场规模:各治疗药物
  • 法国的市场规模
    • 市场规模
    • 整体市场规模
    • 市场规模:治疗药物别
  • 义大利的市场规模
    • 市场规模
    • 整体市场规模
    • 市场规模:各治疗药物
  • 西班牙的市场规模
    • 市场规模
    • 整体市场规模
    • 市场规模:各治疗药物

第18章 日本的市场展望

  • 日本的市场规模
    • 市场规模
    • 整体市场规模
    • 市场规模:各治疗药物

第19章 市场成长要素

第20章 市场阻碍因素

第21章 附录

  • 调查手法

第22章 DelveInsight的服务内容

第23章 免责声明

第24章 关于DelveInsight

目录
Product Code: DIMI0240

DelveInsight's "Acromegaly and Gigantism Therapeutics - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Acromegaly and Gigantism Therapeutics epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Acromegaly and Gigantism Therapeutics Understanding and Treatment Algorithm

The market report provides the overview of the Acromegaly and Gigantism Therapeutics by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Acromegaly and Gigantism Therapeutics Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Acromegaly and Gigantism Therapeutics in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Acromegaly and Gigantism Therapeutics Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Acromegaly and Gigantism Therapeutics Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Acromegaly and Gigantism Therapeutics market.

Acromegaly and Gigantism Therapeutics Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Acromegaly and Gigantism Therapeutics Report Insights

  • Patient Population in Acromegaly and Gigantism Therapeutics
  • Therapeutic Approaches in Acromegaly and Gigantism Therapeutics
  • Acromegaly and Gigantism Therapeutics Pipeline Analysis
  • Acromegaly and Gigantism Therapeutics Market Size and Trends
  • Acromegaly and Gigantism Therapeutics Market Opportunities
  • Impact of upcoming Therapies in Acromegaly and Gigantism Therapeutics

Acromegaly and Gigantism Therapeutics Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Acromegaly and Gigantism Therapeutics Report Assessment

  • Current Treatment Practices in Acromegaly and Gigantism Therapeutics
  • Unmet Needs in Acromegaly and Gigantism Therapeutics
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Acromegaly and Gigantism Therapeutics market
  • Organize sales and marketing efforts by identifying the best opportunities for Acromegaly and Gigantism Therapeutics market
  • To understand the future market competition in the Acromegaly and Gigantism Therapeutics market.

Table of Contents

1. Report Introduction

2. Acromegaly and Gigantism Therapeutics Market Overview at a Glance

  • 2.1. Market Share Distribution of Acromegaly and Gigantism Therapeutics in 2016
  • 2.2. Market Share Distribution of Acromegaly and Gigantism Therapeutics in 2028

3. Disease Background and Overview: Acromegaly and Gigantism Therapeutics

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Acromegaly and Gigantism Therapeutics in 7MM
  • 4.3. Total Prevalent Patient Population of Acromegaly and Gigantism Therapeutics in 7MM - By Countries

5. Epidemiology of Acromegaly and Gigantism Therapeutics by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics
    • 5.1.3. Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics *
    • 5.1.4. Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics *
    • 5.1.5. Diagnosed Cases of the Acromegaly and Gigantism Therapeutics
    • 5.1.6. Treatable Cases of the Acromegaly and Gigantism Therapeutics
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics
    • 5.4.3. Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics *
    • 5.4.4. Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics *
    • 5.4.5. Diagnosed Cases of the Acromegaly and Gigantism Therapeutics
    • 5.4.6. Treatable Cases of the Acromegaly and Gigantism Therapeutics
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics
    • 5.5.3. Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics *
    • 5.5.4. Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics *
    • 5.5.5. Diagnosed Cases of the Acromegaly and Gigantism Therapeutics
    • 5.5.6. Treatable Cases of the Acromegaly and Gigantism Therapeutics
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics
    • 5.6.3. Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics *
    • 5.6.4. Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics *
    • 5.6.5. Diagnosed Cases of the Acromegaly and Gigantism Therapeutics
    • 5.6.6. Treatable Cases of the Acromegaly and Gigantism Therapeutics
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics
    • 5.7.3. Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics *
    • 5.7.4. Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics *
    • 5.7.5. Diagnosed Cases of the Acromegaly and Gigantism Therapeutics
    • 5.7.6. Treatable Cases of the Acromegaly and Gigantism Therapeutics
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics
    • 5.8.3. Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics *
    • 5.8.4. Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics *
    • 5.8.5. Diagnosed Cases of the Acromegaly and Gigantism Therapeutics
    • 5.8.6. Treatable Cases of the Acromegaly and Gigantism Therapeutics
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics
    • 5.9.3. Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics *
    • 5.9.4. Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics *
    • 5.9.5. Diagnosed Cases of the Acromegaly and Gigantism Therapeutics
    • 5.9.6. Treatable Cases of the Acromegaly and Gigantism Therapeutics

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Acromegaly and Gigantism Therapeutics

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Acromegaly and Gigantism Therapeutics

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Acromegaly and Gigantism Therapeutics : 7MM Market Analysis

  • 12.1. 7MM Market Size of Acromegaly and Gigantism Therapeutics
  • 12.2. 7MM Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics
  • 12.3. 7MM Market Sales of Acromegaly and Gigantism Therapeutics by Products

13. Acromegaly and Gigantism Therapeutics : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Acromegaly and Gigantism Therapeutics in United States
    • 13.1.2. Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics in United States
    • 13.1.3. Market Sales of Acromegaly and Gigantism Therapeutics by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Acromegaly and Gigantism Therapeutics in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics in Germany
      • 13.2.1.3. Market Sales of Acromegaly and Gigantism Therapeutics by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Acromegaly and Gigantism Therapeutics in France
      • 13.2.2.2. Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics in France
      • 13.2.2.3. Market Sales of Acromegaly and Gigantism Therapeutics by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Acromegaly and Gigantism Therapeutics in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics in Italy
      • 13.2.3.3. Market Sales of Acromegaly and Gigantism Therapeutics by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Acromegaly and Gigantism Therapeutics in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics in Spain
      • 13.2.4.3. Market Sales of Acromegaly and Gigantism Therapeutics by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Acromegaly and Gigantism Therapeutics in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics in United Kingdom
      • 13.2.5.3. Market Sales of Acromegaly and Gigantism Therapeutics by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Acromegaly and Gigantism Therapeutics in Japan
    • 13.3.2. Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics in Japan
    • 13.3.3. Market Sales of Acromegaly and Gigantism Therapeutics by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Table 7: Treatable Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Table 12: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Table 16: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Table 17: Treatable Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Table 22: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Table 27: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Table 32: Treatable Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Table 37: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 42:7MM- Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 45: United States-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 48: Germany-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 51: France-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 54: Italy-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 57: Spain-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 59:UK-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 60:UK-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 61:UK-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 63: Japan-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Figure 7: Treatable Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Figure 17: Treatable Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Figure 32: Treatable Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 45: United States-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 51: France-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 59:UK-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 60:UK-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 61:UK-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)